Position in NVS
as of Jun 30, 2026
· filed Aug 19, 2026
Position Value
$105,472
New position
Shares Held
673
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#1,370
of 1,603 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bullock Wealth Management Group holds $5,970,093 across 12 Drug Manufacturers - General names. NVS ranks #8 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
2,962 | $3,552,711 | |
| 2 | MRK |
Merck & Co., Inc.
|
4,333 | $556,790 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
3,551 | $448,633 | |
| 4 | JNJ |
Johnson & Johnson
|
1,467 | $372,573 | |
| 5 | ABBV |
AbbVie Inc.
|
1,239 | $311,781 | |
| 6 | AMGN |
Amgen Inc
|
796 | $288,247 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
4,369 | $251,741 | |
| 8 | NVS |
Novartis AG
This page
|
673 | $105,472 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $105,472 | 673 | Shares | Sole | 2026-08-19 | |
| No filing history on record for this holder in this stock. | ||||||